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Abstract
The present study aimed to show the in vivo mechanisms of action of an indole-thiazolidine molecule peroxisome-
proliferator activated receptor pan-agonist (PPAR pan) and cyclooxygenase (COX) inhibitor, LYSO-7, in an ethanol/
HCl-induced (Et/HCl) gastric lesion model. Swiss male mice were treated with vehicle, LYSO-7 or Bezafibrate (p.o.) 1
hour before oral administration of Et/HCl (60%/0.03M). In another set of assays, animals were injected i.p. with an
anti-granulocyte antibody, GW9962 or L-NG-nitroarginine methyl ester (L-NAME) before treatment. One hour after
Et/HCl administration, neutrophils were quantified in the blood and bone marrow and the gastric microcirculatory
network was studied in situ. The gastric tissue was used to quantify the percentage of damaged area, as well as
myeloperoxidase (MPO), inducible nitric oxide synthase (iNOS), endothelial nitric oxide synthase (eNOS) protein and
PPARγ protein and gene expression. Acid secretion was evaluated by the pylorus ligation model. LYSO-7 or
Bezafibrate treatment reduced the necrotic area. LYSO-7 treatment enhanced PPARγ gene and protein expression
in the stomach, and impaired local neutrophil influx and stasis of the microcirculatory network caused by Et/HCl
administration. The effect seemed to be due to PPARγ agonist activity, as the LYSO-7 effect was abolished in
GW9962 pre-treated mice. The reversal of microcirculatory stasis, but not neutrophil influx, was mediated by nitric
oxide (NO), as L-NAME pre-treatment abolished the LYSO-7-mediated reestablishment of microcirculatory blood
flow. This effect may depend on enhanced eNOS protein expression in injured gastric tissue. The pH and
concentration of H+ in the stomach were not modified by LYSO-7 treatment. In addition, LYSO-7 may induce less
toxicity, as 28 days of oral treatment did not induce weight loss, as detected in pioglitazone treated mice. Thus, we
show that LYSO-7 may be an effective treatment for gastric lesions by controlling neutrophil influx and
microcirculatory blood flow mediated by NO.
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Introduction
Gastric ulcers, a chronic disease that affects millions of
people worldwide, are considered a global health problem and
are linked to gastric cancer [1,2]. The genesis of the disease is
associated with an imbalance of endogenous protective agents
and aggressors to the gastric mucosa. Moreover, exogenous
factors, such as stress and the excessive intake of non-
steroidal anti-inflammatory drugs (NSAIDs) or alcohol may also
cause gastric injury. Experimental models using ethanol/HCl
(Et/HCl) to induce gastric ulcers have been recently employed
to study the genesis and progression of gastric lesions and to
evaluate therapeutic approaches [3–7]. Alcohol intake causes
mucosal edema, hemorrhage, sub-epithelial cell exfoliation,
and infiltration of inflammatory cells. These latter cells release
chemical mediators, which contribute to vasoconstriction/
ischemia and stasis in the microcirculation, leading to the death
of gastric cells [8–10].
Nitric oxide (NO) produced in the stomach is strongly
involved in inflammatory and vascular processes, and may
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exert both protective and deleterious effects during gastric
ulceration [11]. Endothelial nitric oxide synthase (eNOS)-
produced NO exerts protective actions by increasing
vasodilatation and blood flow, and also reduces endothelial
leukocyte interactions in the microcirculation [12]. Furthermore,
expression and activation of inducible nitric oxide synthase
(iNOS) by constitutive and recruited cells during gastric
ulceration leads to increased NO expression, which enhances
tissue injury by evoking inflammatory cell infiltration and edema
formation. Thus, the balance between iNOS/eNOS expression
and activity in gastric tissue is important for adequate
production of NO, which contributes to the maintenance of the
structure of gastric tissue in response to aggressive agents
[13,14].
The main currently available gastric ulcer treatment involves
oral administration of histamine receptor antagonists (H2-Ras)
and/or proton pump inhibitors (PIPs), which act by inhibiting
gastric secretion. As gastric ulcers are caused by a complex
mechanism, the search for new therapeutic pathways has been
the target of recent investigations.
Peroxisome proliferator-activated receptor (PPAR) is a
transcription factor of the nuclease hormone receptor
superfamily. Three isoforms have been identified, i.e. PPARα,
PPARβ/δ and PPARγ; they are broadly distributed in the
organism and are responsible for regulating important
physiological process. PPAR isoforms play key roles in the
regulation of adipogenesis, insulin sensitivity and energy
homeostasis [15,16]. Evidence has shown that PPAR regulates
several actions of immune cells, exerting a marked effect on
the control of inflammation. The mechanisms of action are
complex and not yet completely understood, as post-
transcriptional mechanisms have been proposed for the α and
δ isoforms [17,18], and PPARγ activation can induce
transactivation or transrepression of target genes [19–22].
PPAR pan-agonists, which activate all three PPAR isoforms,
have been suggested as a potential tool as they amplify the
therapeutic action and reduce the adverse effects [23,24].
Recent evidence has demonstrated that simultaneous
activation of PPAR isoforms and inhibition of cyclooxygenase-2
(COX-2) may be a good approach to treat inflammatory
diseases and cancer [25,26]. Despite the use of PPAR
agonists in a diversity of inflammatory disorders, only little
evidence has associated PPAR activation by thiazolidine
molecules, such as pioglitazone and rosiglitazone, with the
control and healing of gastric tissue damage. Lesions caused
by ischemia/reperfusion or NSAID intake were reduced in rats
pre-treated with a PPARγ agonist, and the beneficial effect was
correlated to reduced mRNA levels and protein content of pro-
inflammatory cytokines and enzymes, such as COX-2, iNOS,
and oxidative enzymes, as well as overexpression of platelet-
endothelial cell adhesion molecule (PECAM-1) and heat-shock
protein 70 (HSP70) in injured gastric tissue [27–31]. More
recently, it has been shown that rosiglitazone prevents
indomethacin-induced gastric ulcers in type II diabetic rats [32].
Here, we investigated the efficacy and mechanisms of action
of an indole-thiazolidine molecule designed to be a PPAR pan-
agonist and COX inhibitor, named LYSO-7 [33], on Et/HCl-
induced gastric lesions in mice. LYSO-7 provided
cytoprotection by impairing neutrophil influx and reestablishing
the vascular network. The latter effect was mediated by the in
vivo balance of iNOS/eNOS protein expression. To our
knowledge, the proposed mechanism of a PPAR pan-agonist
molecule has not been previously demonstrated in vivo in an
Et/HCl model, and points out the use of PPAR pan-agonists as
a possible therapeutic approach for acute gastric lesions.
Materials and Methods
Animals
Male Swiss mice (20–30 g) were provided by the Central
Animal House of the School of Pharmaceutical Science and the
Chemistry Institute of the University of São Paulo. The animals
were housed in standard cages, at room temperature (25±3°C),
with 12 h dark/12 h light cycles, and supplemented with food
and water ad libitum. They were transferred to the laboratory
12 hours prior to the experiments and were given water ad
libitum. In all experiments, the animals were kept in cages with
raised floors constructed from wide mesh, to prevent
coprophagy.
Ethics statement
The project was approved by the Institutional Animal Care
and Use Committee (IACUC) at the School of Pharmaceutical
Sciences, University of São Paulo (Protocol number: 298 and
399). All procedures were performed according to the Brazilian
Society of Science of Laboratory Animals guidelines for the
proper care and use of experimental animals.
Drug treatments
Bezafibrate, pioglitazone (Sigma, St Louis, MO, USA) and
LYSO-7 [33] were dissolved in water containing 0.5% (v/v)
ethanol absolute, and then added to 2%
carboxymethylcellulose (CMC) in distilled water as the vehicle.
In some cases, before the treatments, the mice were
additionally treated intraperitoneally with L-NG-nitroarginine
methyl ester (L-NAME; Sigma, St Louis, MO, USA), anti-
granulocyte antibody (eBioscience, San Diego, CA, USA) or
GW9962 (Sigma, St Louis, MO, USA).
Gastric lesion protocol
The experiment was carried out according to the method of
Mizui and Doteuchi [34]. After 12 h of fasting, the mice were
randomly divided into six groups of five animals and treated as
follows: 1) naïve (untreated animals); 2) CMC 0.2% aqueous
solution (vehicle, 100 µL/10 g body weight); 3) bezafibrate (25
mg/kg) 4) bezafibrate (50 mg/kg); 5) LYSO-7 (5 mg/kg); 6)
LYSO-7 (25 mg/kg); 7) LYSO-7 (50 mg/kg). One hour after oral
treatment with the above solutions, all animals received ethanol
60% + HCl 0.03 M (100 µL/10g body weight), a concentration
considered relevant to alcohol ingestion in man [35], by the oral
route, to induce gastric ulcers. One hour later, the animals
were sacrificed, and the stomachs were removed and opened
along the greater curvature. The stomachs were gently rinsed
with water to remove the gastric contents and blood clots, and
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then scanned. The images obtained were analyzed using
“EARP” software to measure each lesion.
Determination of gastric secretion
Pylorus ligation is an important procedure that shows
possible changes to gastric content parameters, e.g., total
acidity and pH [36]. The assay employed here was based on a
method described by Shay [37] with a few modifications.
Briefly, the animals were divided into groups (n=5), according
to the treatment used, as previously described. After 18 h of
fasting, the animals were anesthetized; the abdomen was
incised, and the pylorus ligated. Immediately after pylorus
ligation, LYSO-7 was administered at a dose of 50 mg/kg.
Omeprazole (30 mg/kg) was used as the positive control, and
the vehicle was administered as the negative control. All the
samples were administered intraduodenally. Four hours later,
the animals were sacrificed; the abdomen was opened, and
another ligature was placed at the esophageal end. The
stomachs were removed, and the gastric contents were
collected and centrifuged at 3,000 rpm (8,000×g, 25°C, 10
min). The amount of gastric juice acid (in milliliters) and the pH
values were determined. The total acid secretion in the gastric
juice was determined in the supernatant volume by titration (pH
7.0), using a 0.01 M NaOH solution and phenolphthalein as the
indicator.
GW9662 pre-treatment
To evaluate PPARγ agonist activity, animals were pre-
treated with GW9662, an PPARγ antagonist or PBS, 30 min
before treatment with LYSO-7; after 1 hour, the Et/HCl solution
was administered. One hour later, the animals were sacrificed,
and the stomachs were removed and opened along the greater
curvature. The stomachs were gently rinsed with water to
remove the gastric contents and blood clots, and then scanned.
The images obtained were analyzed using “EARP” software to
measure each lesion.
Histological analysis
After macroscopic analysis, a small portion of each stomach
was ﬁxed in 4% formalin solution, dehydrated through
increasing grades of alcohol and embedded in parafﬁn. Five-
micrometer sections were made using a microtome, and
stained with hematoxylin–eosin solution. Tissue preparations
were observed and micro-photographed using an Axioplan 2
Zeiss light microscope. Five different fields of the tissue were
evaluated to count the number of leukocytes.
Myeloperoxidase (MPO) assay
The activity of myeloperoxidase (MPO), a hemoprotein
located in the azurophilic granules of neutrophils, was used as
a biochemical marker for neutrophil inﬁltration into the studied
tissues. MPO activity was measured according to the method
originally described by Bradley [38] with some modiﬁcations,
after heating the organ homogenates at 60°C for 2 h in order to
inactivate endogenous catalase. Brieﬂy, after homogenizing the
tissue samples in the presence of hexadecyl trimethyl
ammonium bromide (HTAB, Sigma, St Louis, MO, USA) in
order to disrupt the granules, the tubes were centrifuged at
10,000 x g for 5 min. MPO activity was analyzed in the
supernatants by its capacity to catalyze the oxidation of o-
dianisidine dihydrochloride (Sigma, St Louis, MO, USA) in the
presence of hydrogen peroxide. Absorbance was monitored at
460 nm (Spectramax Plus 384, Molecular Devices Inc.,
Sunnyvale, USA) and the obtained Vmax (maximum speed)
parameter, related to enzyme activity, was determined using a
molar extinction coefﬁcient of 11,300 M cm-1.
Anti-granulocyte antibody treatment
To determine whether neutrophil depletion encompasses the
entire period of neutrophil infiltration, test mice were injected
with 50 µL (0.025 mg) of rat anti-mouse Ly6G (Gr-1) antibody,
clone RB6-8C5 (eBioscience, San Diego, CA, USA), 48 h
before the experiment. Previous findings showed that this
Ly6G/Ly6C antibody specifically depletes mature granulocytes,
especially neutrophils, and does not influence the total
monocyte/macrophage count [39,40]. Control mice were
injected with 50 µL of PBS. Neutrophil depletion was confirmed
by optical microscopy.
Intravital microscopy
Animals were anesthetized with ketamine:xylazine (0.2:0.02
g/kg body weight), injected intraperitoneally, and
tracheostomized to facilitate respiration. The femoral vein was
cannulated to inject the fluorescent agent rhodamine.
Leukocytes were labeled with 0.02% rhodamine immediately
before blood vessel visualization. A portion of the stomach was
surgically exteriorized to allow observation of the
microcirculation. Animals were maintained on a special board
thermostatically controlled at 37°C. The preparation was kept
moist and warmed by irrigating the tissue with a warmed (37°C)
Tyrode’s solution (in mg/mL: 8 NaCl; 0.2 KCl; 0.1 MgCl2; 0.058
NaH2PO4.H2O; 1 glucose; 1 NaHCO3) (pH 7.2–7.4). The rate of
solution flow onto the exposed tissue was controlled (2 mL/min)
to keep the preparation in continuous contact with solution.
Images were obtained by fluorescence microscopy (Carl-Zeiss,
Axioplan II) with epi-illumination, captured with a video camera
and simultaneously transmitted to a computer. Assays were
performed with animals submitted to the Et/HCl-induced ulcer
model, pre-treated or not with L-NAME, and treated or not
treated with LYSO-7. Five different fields of the microcirculation
were evaluated to determine the percentage of blood vessels in
stasis.
PPARγ mRNA expression
PPARγ mRNA transcripts were quantified in stomach tissue
samples by real-time reverse transcription polymerase chain
reaction (RT-PCR) analysis as previously reported. The
samples were stored at −80°C in RNA-free Eppendorf tubes
containing a lysis and nucleic acid purification solution (Lysis
Solution 2X), homogenized by centrifugation and then digested
with proteinase K (200 µg mL−1 in lysis solution) overnight at
room temperature. Samples were centrifuged at 14,000 rpm for
5 min and the aqueous phase containing RNA was recovered.
Total RNA extraction was performed with an ABI PRISM 6100
Nucleic Acid Prepstation (Applied Biosystems, USA) and its
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related chemistry. RNA was dried using a UNIVAPO 100H drier
(UNIEQUIP). Subsequently, the RNA was dissolved in RNAse-
free water (DEPC water) and quantified with a Nanodrop
spectrophotometer (ND-420, Nanodrop Technology). Nucleic
acid quality was assessed by measuring the A260/A280 ratio.
Ten microliters of total RNA were used for the RT reaction
following the manufacturer’s protocol (High Capacity cDNA
Archive kit, Applied Biosystems, USA). The cDNA was then
amplified by real-time PCR. The reaction mix (all reagents from
Applied Biosystems) contained TaqMan DNA polymerase
(TaqMan® Universal PCR Master Mix 2X) and primers. Real-
time PCR was performed with an ABI PRISM 7000 Sequence
Detection System (Applied Biosystems, USA).
iNOS, eNOS and PPARγ protein expression
iNOS, eNOS and PPARγ protein expression in the stomach
was quantified by Western blot. Briefly, stomach tissue proteins
were extracted in Tris buffer (50 mM, pH 7.4) containing
leupeptin (10 µg/mL), soybean trypsin inhibitor (10 µg/ml),
aprotinin (2 µg/ml) and PMSF (1 mM). Homogenized proteins
(87.5 µg) were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS–PAGE; 7%) and were
electrophoretically transferred to a nitrocellulose membrane.
After blocking non-specific sites with 1% casein, membranes
were incubated overnight with primary rabbit polyclonal
antibodies raised against iNOS (BD, CA, USA), eNOS (BD,
CA, USA) and PPARγ (Santa Cruz Biotechnology, INC, CA,
USA) (500 ng/mL). Membranes were washed with Tris-buffered
saline containing 0.1% Tween-20 and incubated with
horseradish peroxidase-conjugated goat anti-rabbit secondary
antibody. A chemiluminescent assay (HRP
SuperSignalWestPico; Pierce, USA) was used to detect
immunoreactive bands. The intensities of the bands were
estimated by densitometry analysis and were compared to the
intensity of β-actin expression.
Effects of LYSO-7 chronic treatment on body weight
To evaluate possible adverse effects associated with
LYSO-7 administration (50 mg/kg, oral route), the animals were
treated daily for 28 days by the oral route. Body weight and
food consumption were assessed every two days. Animals
treated with pioglitazone (40 mg/kg, oral route) were used as
the control.
Statistical analysis
The means and standard error of the mean (SEM) of all data
presented here were compared using Student’s t-test or
ANOVA. Tukey’s multiple comparisons test and Dunnett’s test
was used to determine the signiﬁcance of differences between
values according to the experimental conditions. The statistical
software GraphPad Prism® was used for this purpose. p<0.05
was considered signiﬁcant.
Results
In vivo LYSO-7 treatment protects Et/HCl-induced
gastric tissue damage
Oral administration of Et/HCl solution caused lesions in the
gastric tissue, which were prevented in a dose-dependent
manner by LYSO-7 pre-treatment (Figure 1). It is noteworthy
that tissue protection was seen with 25 mg/kg of LYSO-7 and
with 50 mg/kg of bezafibrate, a PPAR pan-agonist (Figure 1).
In vivo LYSO-7 treatment enhances PPARγ gene and
protein expression in the gastric tissue
Tissue PPAR expression has been highlighted as a
mechanism of action of PPAR agonists. Here, we show that
this is a mechanism of action of LYSO-7, as levels of PPAR
mRNA and protein in the gastric tissue were markedly
enhanced after in vivo LYSO-7 treatment (Figure 2). In
addition, we show that the effect of LYSO-7 in Et/HCl-induced
gastric lesions is dependent on its PPARγ agonist activity, as
the protective effect of LYSO-7 in gastric tissue was reversed
in mice pre-treated with GW9962, a recognized antagonist of
PPARγ (Figure 3A and B).
LYSO-7 does not impair acid gastric secretion
Data presented in Table 1 show that the pH and H+
concentration in the stomach after pylorus ligation surgery were
3.26 and 135.0, respectively. These values were modified by
omeprazole treatment, represented by increased and reduced
pH and H+ concentration, respectively. On the other hand,
LYSO-7 treatment did not affect gastric secretion parameters.
LYSO-7 inhibits neutrophil migration into Et/HCl-
damaged gastric tissue
Although neutrophil participation in Et/HCl-induced gastric
damage has been proposed, its actual role in the process has
not been previously shown. Here, we show that neutrophil is a
hallmark of the lesion, as administration of an anti-granulocyte
monoclonal antibody into mice markedly reduced both the
number of granulocytes in the blood (Figure 4A) and in the
gastric lesion 48 hours later (Figure 4B and C). Moreover,
histological images and enhanced MPO activity in the gastric
tissue showed that neutrophils rapidly accumulated in the
tissue after Et/HCl administration, which were reduced by
LYSO-7 treatment (Figure 5A, B and C). LYSO-7 acts by
blocking neutrophil trafficking from the bone marrow, as a
reduced number of circulating neutrophils and enhanced
number of mature granulocytes in the bone marrow were
observed in LYSO-7 treated mice (Figure 5 D and E).
LYSO-7 reverses blood flow stasis in Et/HCl-damaged
gastric tissue, mediated by NO
The real-time intravital microscopy on the whole stomach
carried out in this study is different than methods previously
reported in the literature [41], as it does not involve surgical
manipulation, but only exteriorization of the tissue. The data
obtained here show that the Et/HCl administration caused rapid
stasis in the microcirculatory network (Figure 6 A and B), and
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LYSO-7 pre-treatment prohibited vessel stasis (Figure 6 A and
B).
NO has been proposed as protective endogenous mediator
of gastric damage induced by different agents. Here, we show
that pre-treatment with L-NAME, a non-specific inhibitor of NO
Figure 1.  Effect of LYSO-7 on Et/HCl-induced gastric tissue damage.  Male Swiss mice were treated with CMC (vehicle),
LYSO-7 or bezafibrate, p.o., 1 hour before oral administration of Et/HCl solution. Gastric tissue was collected 1 hour after Et/HCl
administration. (A) shows the percentage of the lesioned area and (B) shows representative images of the gastric tissue. Results
are expressed as mean±SEM of 5 animals in each group. Statistical analysis was performed using ANOVA followed by Dunnett’s
test. *P<0.01 vs. vehicle.
doi: 10.1371/journal.pone.0076894.g001
Figure 2.  Effects of LYSO-7 treatment on PPARγ gene and protein expression in Et/HCl-damaged gastric tissue.  Male
Swiss mice were treated with CMC (vehicle) or LYSO-7, p.o., 1 hour before oral administration of Et/HCl solution, and gastric tissue
was collected 1 hour later. (A) PPARγ gene expression and (B and C) PPARγ protein expression. Results are expressed as mean
±SEM of 4 animals in each group. Statistical analysis was performed using ANOVA followed by Tukey’s test. *P<0.05 vs. vehicle.
doi: 10.1371/journal.pone.0076894.g002
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synthesis, enhanced gastric lesions caused by Et/HCl
administration and partially inhibited the protective effect of
LYSO-7 (Figure 6C and D). Furthermore, L-NAME treatment
blocked the action of LYSO-7 on gastric microcirculatory blood
flow (Figure 6E and F), but did not alter the reduced neutrophil
influx into the gastric area caused by LYSO-7 (Figure 6 G).
LYSO-7 treatment inhibits iNOS expression and enhances
eNOS protein expression in Et/HCl-damaged gastric tissue
Based on the evidence supporting a role for NO in the
protective effects of LYSO-7 in Et/HCl-damaged gastric tissue,
and since eNOS/iNOS imbalance is involved in gastric ulcer
disease, the actions of LYSO-7 on the protein expression of
NOS enzymes were investigated in gastric tissue. The data
presented in Figure 7 show that LYSO-7 inhibited iNOS and
enhanced eNOS protein expression.
LYSO-7 treatment does not alter body weight
In order to evaluate a possible adverse effect of LYSO-7,
changes in body weight were evaluated for 28 days. The data
show that LYSO-7 treatment did not alter the cumulative weight
change or food intake. In contrast, pioglitazone treatment
evoked significant weight loss, which was not dependent on
impaired feed intake (Figure 8).
Figure 3.  Role of PPARγ receptor in the protective effect of LYSO-7 on Et/HCl-induced gastric tissue damage.  Male Swiss
mice were pretreated with GW9962 or PBS (i.p.) and treated with CMC (vehicle) or LYSO-7 20 min later. Et/HCl solution was
administered 1 hour after the treatments. Gastric tissue was collected 1 hour later. (A) shows the percentage of the lesioned area;
(B) shows representative images of the gastric tissue. Results are expressed as mean±SEM of 5 animals in each group. Statistical
analysis was performed using ANOVA followed by Dunnett’s test **P<0.01 vs. vehicle.
doi: 10.1371/journal.pone.0076894.g003
Table 1. Effects of LYSO-7 and omeprazole treatment on biochemical parameters of gastric juice obtained from mice with
pylorus ligation.
Treatment Dose pH [H+] mequiv./L/4h
 (mg/kg)   
Vehicle - 3.26 ± 0.12 135.0 ± 10.41
Omeprazole 30 4.24 ± 0.19* 62.5 ± 5.18*
LYSO-7 50 3.32 ± 0.17 117.5 ± 18.33
Results are mean±SEM of 5 mice in each group. Statistical analysis was performed using ANOVA followed by Dunnett’s test *p<0.05 vs. vehicle
doi: 10.1371/journal.pone.0076894.t001
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Discussion and Conclusions
The effectiveness of preventive and therapeutic approaches
for gastric ulcers has been limited to one pathway, i.e. proton
pump inhibition, and the adverse effects of drugs [42]. Using an
acute experimental model of gastric lesions, we show here that
a indole-thiazolidine molecule, a PPAR pan-agonist and COX
inhibitor named LYSO-7, does not affect gastric secretion, but
causes cytoprotection by inhibiting neutrophil influx into the
injured area and by maintaining blood flow in the gastric
microcirculatory network. The latter effect is mediated by NO,
which seems to be produced by eNOS.
Figure 4.  Role of neutrophils in Et/HCl-damaged gastric tissue.  Male Swiss mice were pre-treated with PBS or anti-
granulocyte antibody (i.p.) and blood was collected 24 or 48 hours later; Et/HCl solution was orally administered a further 48 hours
later. Gastric tissue was collected 1 hour after Et/HCl delivery. (A) number of neutrophils in the blood; (B) percentage of the gastric
lesion and (C) representative images of gastric tissue. Results are expressed as mean±SEM of 5 animals in each group. Statistical
analysis was performed using ANOVA followed by Tukey’s test. *P<0.05 and ***P<0.001 vs. PBS treatment.
doi: 10.1371/journal.pone.0076894.g004
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The thiazolidine-2,4-dione region of the thiazolidione
molecule binds to the retinoid X receptor (RXR) coupled to
PPARs to form heterodimeric complexes, which then bind to
the peroxisome proliferator response element (PPRE) gene
promoter, leading to the regulation of gene transcription
[43,44]. Although LYSO-7 maintains the thiazolidine-2,4-dione
group, it is an indole-substituted properly synthesized to also
display inhibitory activity against COX [33]. In vitro studies had
already shown the PPAR pan-agonist activity of LYSO-7 [33],
and here we confirm that the activity is maintained in vivo, as
levels of PPARγ gene and protein expression were enhanced
by LYSO-7 treatment. It is noteworthy that the expression of
PPAR is a known end-point of PPAR activation [16]; however,
the effect of a PPAR pan-agonist on gastric tissue has been
shown here for the first time. Furthermore, we have shown that
the cytoprotective effect of LYSO-7 is dependent on PPARγ, as
the in vivo antagonism of the receptor by GW9962 abolished
the inhibitory action of LYSO-7 in Et/HCl-induced ulcers. These
data corroborate the notion that the γ isoform seems to be the
main class of PPAR in gastric tissue [27–31]. It is worth
mentioning that GW9962 has been previously used to
determine the PPAR agonistic activity of newly synthesized
compounds and to clarify the mechanisms of action of PPARγ
[45–49].
Neutrophil influx has been observed in several models of
gastric ulcers, and they have been thought to act as an inducer
of the harmful process [50,51]. The participation of neutrophils
in acute Et/HCl-induced gastric lesions in mice was shown
here, as they rapidly accumulated in the injured tissue and in
vivo neutrophil depletion significantly reduced the injured area.
Together, these data corroborate the idea that inhibition of
neutrophil recruitment may be a target for anti-gastric ulcer
therapy [52,53], and that this can be modulated by LYSO-7
treatment.
The role of PPAR activation on neutrophil influx has been
shown in different models of inflammation, and the majority of
them show an inhibitory effect on the process [19,21,54]. The
mechanisms involve the direct inhibition of leukocyte-
endothelial interactions and chemotaxis [55,56] or impaired
chemotactic mediator secretion [57–59]. Our data show, for the
Figure 5.  Effects of LYSO-7 on neutrophil influx into Et/HCl-damaged gastric tissue.  Male Swiss mice were treated with CMC
(vehicle) or LYSO-7, p.o., 1 hour before oral administration of Et/HCl solution and gastric tissue, blood and bone marrow perfusate
were collected 1 hour later. (A) MPO activity in the gastric tissue; (B) leukocyte numbers in the gastric tissue; (C) representative
image of leukocyte infiltration in the gastric tissue; (D) numbers of granulocytes in the bone marrow; (E) number of circulating
neutrophils. Results are expressed as mean±SEM of 5 animals in each group. Statistical analysis was performed using ANOVA
followed by Tukey’s test. *P<0.05; **P<0.01 vs. vehicle; # P<0.05; # # P<0.01 vs. naïve.
doi: 10.1371/journal.pone.0076894.g005
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first time, that a PPAR agonist affects the trafficking of
neutrophils from the bone marrow, as gastric-injured mice pre-
treated with LYSO-7 presented higher and lower numbers of
neutrophils in the bone marrow and blood, respectively. Our
previous results indicate that LYSO-7 may act directly on the
locomotory functions of neutrophils. N-formyl-l-methionyl-l-
leucyl-l-phenylalanine (fMLP)-induced leukocyte-endothelial
interactions in the mesenteric microcirculation are impaired in
LYSO-7 treated rats, depending on reduced gene and protein
expression of the CD62L and CD18 adhesion molecules by
neutrophils (Farsky et al., personal communication). The
results obtained in the present study contribute to this
evidence, as the inhibitory effect on neutrophil trafficking was
not dependent on NO mediation. The reduced neutrophil influx
into gastric lesion caused by LYSO-7 was not modified by in
vivo L-NAME treatment.
Figure 6.  Effects of LYSO-7 on microcirculatory blood flow in Et/HCl-damaged gastric tissue.  Male Swiss mice were pre-
treated with L-NAME (i.p.) or treated with CMC (vehicle) or LYSO-7, p.o., 1 hour before oral administration of Et/HCl solution.
Gastric tissue was surgically exposed 1 hour later after treatments for observation by intravital microscopy. (A) percentage of
vessels in stasis; (B) representative images of microcirculatory vessels in the gastric tissue; (C) percentage of lesion area; (D)
representative images of gastric tissue; (E) percentage of vessels in stasis; (F) representative images of microcirculatory vessels in
the gastric tissue (G) MPO activity in gastric tissue. White arrows indicate vessels in stasis. Results are expressed as mean±SEM of
5 animals in each group. Statistical analysis was performed using ANOVA followed by Tukey’s test. **P<0.01 vs. vehicle; *P<0.05
vs. vehicle + L-NAME and # # P<0.01 vs. naïve.
doi: 10.1371/journal.pone.0076894.g006
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In contrast, maintenance of the surface mucosal
microcirculatory blood flow by LYSO-7 treatment occurred via
NO mediation, and seemed to be dependent on reduced and
increased protein expression of iNOS and eNOS, respectively.
A beneficial role of NO on gastric ulcers has been shown, as
the in vivo blockade of both eNOS and iNOS favors the
development of gastric lesions and treatments with NO donors
heal lesions [60–62]. Although it has been shown that
enhanced activities of iNOS and eNOS in arthritic rats are
responsible for the aggravation of cold-resistant stress-induced
gastric lesions [61], most studies have demonstrated that a
shift in the eNOS/iNOS balance protects gastric tissue
Figure 7.  Effects of LYSO-7 on NOS expression in Et/HCl-damaged gastric tissue.  Male Swiss mice were treated with CMC
(vehicle) or LYSO-7, p.o., 1 hour before oral administration of Et/HCl solution and gastric tissue was collected 1 hour later. (A)
iNOS; (B) eNOS protein expression on gastric tissue (C) representative image of gel electrophoresis. Results are expressed as
mean±SEM of 4 animals in each group. Statistical analysis was performed using ANOVA followed by Tukey’s test. *P<0.05 vs.
vehicle and # p<0.05 vs. naïve.
doi: 10.1371/journal.pone.0076894.g007
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[13,62,63]. These data are corroborated here, as LYSO-7
promoted a shift in eNOS/iNOS expressed proteins in gastric
tissue. It has been shown that PPAR selective agonists favor
the shift of the eNOS/iNOS balance in renal tissue after
ischemia–reperfusion injury, in endothelial cells after glycation-
end product activation, and during vasoconstriction in
mesentery vessels [64–67]. Nevertheless, it seems that
activation of the three isoforms of PPAR are involved in NO-
mediated gastroprotection, as the shift in eNOS/iNOS
expression and the reversion of glutathione peroxidase and
reductase levels in the damaged stomach were not detected
after equivalent treatment with pioglitazone, a selective PPARγ
agonist (data not shown). Further assays are being carried out
to confirm this hypothesis.
The development of PPAR pan-agonists has been focused
on the reduction of adverse effects, as they act as partial
agonists of two or more isoforms of the receptor [23,68].
Although the data are preliminary, LYSO-7 did not modify body
weight, which was reduced by equivalent treatment with
pioglitazone. In addition, no alterations to biochemical and
hematological parameters or on the morphology of the heart,
spleen, liver, lung and kidney were observed (data not shown).
Considering that the therapeutic efficacy of PPAR agonists is a
worrying challenge [68], additional toxicity and kinetics assays
were performed to assure the efficacy of LYSO-7.
In summary, we have shown the in vivo actions of LYSO-7
on the mechanisms of gastric ulcer pathogenesis. We have
also demonstrated that inhibition of neutrophil migration and a
shift in the eNOS/iNOS balance completely abrogate gastric
tissue lesions. Based on the mechanism elucidated here,
LYSO-7 may be employed to treat neutrophil-mediated
diseases and to reestablish damaged microcirculatory
networks.
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